OncoMatch/Clinical Trials/NCT07071038
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
Is NCT07071038 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Switch for breast cancer.
Treatment: Switch — Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor. An aromatase inhibitor is hormone therapy that lowers the chance of breast cancer coming back (recurring) after surgery by blocking an enzyme in fat tissue called aromatase; aromatase changes other hormones in the body to estrogen. Women who do not complete the standard 5-year treatment are at higher risk of their cancer coming back. The goal of this research is to prevent breast cancer from coming back after surgery by helping women to stay on treatment with aromatase inhibitors. Researchers believe the best path to help women to stay on treatment is to create a better way to manage (control) side effects.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (estrogen receptor alpha (ER)-positive)
The DCIS or invasive cancer must be estrogen receptor alpha (ER)-positive
Required: HER2 (ERBB2) negative (IHC 0-1+, or with a FISH ratio of <1.8 if IHC is 2+ or if IHC has not been done) (HER2-negative)
The invasive cancer must be HER2-negative (IHC 0-1+, or with a FISH ratio of <1.8 if IHC is 2+ or if IHC has not been done)
Disease stage
Required: Stage I, II, III, DCIS
Prior therapy
Cannot have received: endocrine therapy
Exception: none in the last 10 years
Prior endocrine therapy for any histologically-confirmed cancer or prevention of breast cancer in the last 10 years is not allowed.
Cannot have received: adjuvant therapy
Exception: Bisphosphonate or denosumab treatment for metabolic bone issues are allowed.
Any other adjuvant therapy for breast cancer. Exception: Bisphosphonate or denosumab treatment for metabolic bone issues are allowed.
Cannot have received: endocrine therapy (tamoxifen)
Patients who are prescribed tamoxifen as the first endocrine therapy rather than an aromatase inhibitor.
Lab requirements
Blood counts
ANC >1,000/mm3 and platelet count > 75,000/mm3
Liver function
Total bilirubin <1.5 x ULN; ALT and AST < 3 x ULN.
Absolute neutrophil count (ANC) >1,000/mm3 and platelet count > 75,000/mm3; Total bilirubin <1.5 x ULN; ALT and AST < 3 x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dartmouth Cancer Center · Lebanon, New Hampshire
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify